Albert Do MD, MPHAssistant Professor of Medicine, Section of Digestive Diseases, Department of Internal Medicine; Clinical Director, Yale Fatty Liver Disease Program, Yale University School of Medicine, New Haven, Connecticut
Dr. Do received his Bachelor’s Degrees in Molecular and Cell Biology and Psychology at the University of California at Berkeley and a medical doctorate and Master’s in Public Health at Boston University. He completed his residency and fellowship training at Yale University, concurrently obtaining board certification in obesity medicine.
He is the Clinical Director of the Yale University Fatty Liver Disease Program, and has expertise and interest in hepatology, obesity medicine, gastroenterology, and general internal medicine. He is particularly interested in all forms of fatty liver disease, including nonalcoholic fatty liver disease and associated obesity, as well as alcohol-associated fatty liver disease, which are significant clinical and public health problems. He also is interested in clinical research, in particular the development of observational cohorts and epidemiological research with large databases. Dr. Do has been recognized with several awards including the American Association for the Study of Liver Diseases (AASLD) Emerging Liver Scholar Award, the American Gastroenterological Association (AGA) Young Investigator Award, and the Yale School of Medicine Samuel Kushlan Award for Excellence in research.
DisclosuresDr. Do has no relevant disclosures.
Recent Contributions to PracticeUpdate:
- Effect of Diabetes Medications and Glycemic Control on Risk of HCC in Patients With NAFLD
- Effect of Tirzepatide on Liver Fat Content and Abdominal Adipose Tissue in Patients With Type 2 Diabetes
- Effect of Diabetes on NAFLD Development and Progression
- Combination Therapy With Pioglitazone/Exenatide Metformin and Hepatic Fibrosis and Steatosis Prevalence
- Identification of NAFLD in Patients Without Diabetes